Clinical

Supported organisms

The portal accepts coded submissions for:

Enterococcus faecium
Staphylococcus aureus
Klebsiella pneumoniae
Acinetobacter baumannii
Pseudomonas aeruginosa
Enterobacter species
Escherichia coli

The portal supports operational coordination only. It is not an emergency service, does not provide medical advice, and does not replace a physician's clinical or regulatory judgment. A recorded laboratory match does not establish clinical benefit, safety, treatment suitability, or phage availability.

Expanded Access Policy

Last updated: July 2026

Expanded access (sometimes referred to as “compassionate use”) is a regulatory pathway administered by the U.S. Food and Drug Administration (FDA) that may permit the use of an investigational product for certain patients with serious or immediately life-threatening diseases or conditions when no comparable or satisfactory treatment options are available and participation in an appropriate clinical trial is not feasible.

Expanded access is not a treatment program and does not guarantee that an investigational product will be available or provided.

How requests are submitted

Treating physicians or patients can submit inquiries to expandedaccess@tabulabio.com

Patients and family members interested in investigational phage therapy should discuss potential treatment options with their treating physician. Tabula cannot provide medical advice.

Please do not submit protected health information through general email. If additional clinical information is required for evaluation, Tabula will provide instructions for secure transmission.

General evaluation criteria

Each request is evaluated individually. Factors that may be considered include:

whether the patient has a serious or immediately life-threatening bacterial infection;
whether available treatment options have been exhausted, are unsuitable, or are unlikely to provide satisfactory benefit, as determined by the treating physician;
whether participation in an appropriate clinical trial is unavailable or not feasible;
whether sufficient scientific information exists to reasonably evaluate the request;
whether an investigational phage candidate can be identified and manufactured for the patient’s bacterial isolate;
whether manufacturing capacity, product availability, quality requirements, and logistical considerations permit access;
whether providing expanded access would not interfere with the ongoing development of the investigational therapy or conduct of clinical studies; and
whether applicable regulatory, ethical, institutional, and legal requirements can be satisfied.

These considerations are general guidelines only. Additional information may be requested, and other factors may be considered as appropriate.

Company response

Tabula will acknowledge receipt of a physician’s inquiry within two (2) business days. Following receipt of sufficient information to permit evaluation, Tabula will provide an initial decision or request additional information within five (5) business days.

Important limitations

Submission of a request does not guarantee that:

an investigational phage candidate can be identified;
an investigational product is available;
the request will be approved by Tabula;
FDA authorization or other required approvals will be obtained; or
treatment will occur.

Tabula may revise, suspend, or discontinue this policy at any time without prior notice. Nothing in this policy creates any obligation for Tabula to provide an investigational product to any individual patient.